title: [Inhibition of platelet aggregation].
abstract: Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in diabetic patients according to current scientific evidence.
authors.affiliation: 1. Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich. thomas.wascher1@chello.at.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Wascher
authors.affiliation: Abteilung für Innere Medizin und Kardiologie/VIVIT-Institut, Landeskrankenhaus Feldkirch, Feldkirch, Österreich.
authors.forename: Christoph H
authors.initials: CH
authors.lastname: Säly
mesh_terms: D001317:Austria; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: Acute atherothrombosis; Diabetes mellitus; Platelets anti platelet drugs